AUA 2018: Prognostic Impact of Bleomycin Pulmonary Toxicity on the Outcome of Patients with Testicular Cancer

San Francisco, CA (UroToday.com) Dating back to the 1980’s, bleomycin, etoposide and cisplatin (BEP) chemotherapy has been the standard of care for treatment of patients with metastatic testicular cancer. The pulmonary side effects of bleomycin are well-established. A recent review highlighted that bleomycin toxicity is associated with: (i) cumulative bleomycin dose, (ii) renal function, (iii) age, and (iv) smoking status [1].

AUA 2018: Factors Associated with Early Mortality and Survival Outcomes Among Patients with Testicular Neoplasms

San Francisco, CA (UroToday.com) The group from Princess Margaret Cancer Centre in Toronto, Canada presented their >4-decade population-based study assessing predictors of early mortality among patients diagnosed with testicular neoplasms. Since Dr. Lawrence H. Einhorn’s landmark chemotherapy studies of the 1970’s and 1980’s that remarkably improved survival among testis cancer patients, the long-term survival rates generally exceed 95%.  However, despite these extraordinary survival outcomes, there is a small subset of patients that will still suffer mortality from testis cancer.

AUA 2018: Outcomes and Factors Associated with Receipt of Open vs Minimally Invasive RPLND for Testis Cancer

San Francisco, CA (UroToday.com) Retroperitoneal lymph node dissection (RPLND) for testis cancer remains one of the most complex operations performed in urologic oncology practice. Over the past decade or so, several centers have described their use of laparoscopic RPLND, typically in the setting of primary RPLND or low volume retroperitoneal disease. With increasing surgeon comfort with the da Vinci robotic platform, several reports have emerged in the past couple of years describing robotic RPLND, which is a more favorable minimally invasive approach considering the length and technical dissection associated with these procedures.